Printer Friendly

MGI PHARMA ACQUIRES NEW CRITICAL CARE DRUG; MGI 330 COULD IMPROVE DIAGNOSIS OF HEART DISEASE AND RECOVERY FROM ISCHEMIA

 MGI PHARMA ACQUIRES NEW CRITICAL CARE DRUG; MGI 330 COULD IMPROVE
 DIAGNOSIS OF HEART DISEASE AND RECOVERY FROM ISCHEMIA
 MINNEAPOLIS, Feb. 26 /PRNewswire/ -- MGI Pharma, Inc. (NASDAQ: MOGN) today announced that it has acquired the rights to three patents for the use of MGI 330 (ribose) as a new critical care drug.
 One patent covers the use of MGI 330 to improve the speed, safety and accuracy of diagnosing heart disease by improving the effectiveness of thallium imaging. Thallium imaging is used to detect compromised heart tissue that may be preserved by therapeutic procedures such as coronary bypass and angioplasty.
 The other two patents cover the use of MGI 330 to improve the speed and ability of tissue to recover from temporary ischemia (inadequate blood supply).
 "MGI 330 is an exciting addition to our product portfolio," said Dr. Charles C. Muscoplat, MGI Pharma's executive vice president, New Business Development. "MGI 330 has the potential to be a medically significant product because of its promise of improving the quality of life for certain critically ill patients."
 MGI Pharma's strategy tries to reduce the risks of drug development. They look for products that address unsatisfied needs, have some history of safety and efficacy data, and are exploitable in speciality areas of medicine. Dr. Kenneth F. Tempero, MGI Pharma's chairman and CEO, stated that "MGI 330 has satisfied our corporate acquisition requirements and, hopefully, will prove to be an important addition to the overall growth of the company." MGI 330 would be marketed to the subspecialty areas of nuclear medicine and invasive cardiology.
 MGI Pharma acquires, develops and markets pharmaceuticals prescribed and recommended by physician specialists. The company currently sells DIDRONEL(R) I.V. Infusion ad Oratect(TM) Gel and recently submitted a New Drug Application to the Food and Drug Administration for Salagen(TM), a treatment for radiation-induced xerostomia.
 -0- 2/26/92
 /CONTACT: Lori Weiman of MGI Pharma, 612-939-4666/
 (MOGN) CO: MGI Pharma, Inc. ST: Minnesota IN: MTC SU:


DS -- MN004 -- 2667 02/26/92 09:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 26, 1992
Words:337
Previous Article:GERMANY AUTHORIZES VIRAZOLE FOR TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS
Next Article:PENNDOT: SIGN WORK TO CLOSE LANE AND OFF-RAMP
Topics:


Related Articles
MGI PHARMA CHEMOPROTECTIVE (MGI 136) PROGRAM REMAINS ON TRACK; COMPANY COMMENTS ON FDA ADVISORY COMMITTEE MEETING ON ETHYOL(R)
MGI PHARMA SUSPENDS MGI 136 CLINICAL STUDIES
MGI PHARMA'S SALAGEN(TM) DESIGNATED ORPHAN DRUG FOR SJOGREN'S SYNDROME
MGI PHARMA ACQUIRES RIGHTS TO POTENTIAL NEW DRUG FOR CHRONIC DRY MOUTH; PRODUCT IN EARLY STAGE OF DEVELOPMENT
MGI PHARMA REPORTS FIRST QUARTER 1993 RESULTS
MGI PHARMA ANNOUNCES ACQUISITION OF NEW ANTI-ESTROGENIC CANCER AGENTS AT 1993 ANNUAL MEETING
MGI PHARMA ACQUIRES EARLY STAGE COMPOUNDS WITH POTENTIAL TO BECOME BREAKTHROUGH ANTI-CANCER TREATMENT
MGI PHARMA ANNOUNCES 1993 RESULTS
MGI PHARMA's SALAGEN(R) TABLETS CLEARED FOR MARKETING BY FDA; PRODUCT TREATS RADIATION-INDUCED DRY MOUTH IN HEAD AND NECK CANCER PATIENTS
MGI PHARMA ANNOUNCES ITS SAMPLING PROGRAM IS IMPACTING INITIAL PIPELINE DRAW DOWN OF SALAGEN TABLETS, LEADING TO LOWER THIRD QUARTER SALES

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters